N/A
Completed N=9
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
Metastatic Malignant Neoplasm in the Brain · Brain Cancer
Source: ClinicalTrials.gov NCT02167204 ↗
Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcomePrimary: Percentage Change in Measure of FLT Flux — -4; 3 percent change
Summary
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with brain tumors. Comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change in Measure of FLT Flux |
-4; 3 | — |
| PRIMARY Percentage Change in Measure of Reflecting Transport |
-11; -11 | — |
| PRIMARY Percentage Change in Measure of Standard Uptake Value |
-14; -10 | — |
| PRIMARY Survival |
23.2 | — |
| PRIMARY Clinical Response Assessed Using Revised Assessment in Neuro-Oncology Criteria |
— | — |
Eligibility Criteria
Inclusion Criteria
- Have a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or metastatic) by standard clinical diagnosis such as pathology or imaging
- Planned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combined
Exclusion Criteria
- Inability to provide informed consent
- Pregnancy
- Inability to lie still for the imaging study
- Weight over 350 lbs.
Data sourced from ClinicalTrials.gov (NCT02167204). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.